Sclerostin Dynamics in Metabolic Bone Disorders

Sclerostin, a glycoprotein predominantly secreted by osteocytes, serves as a critical inhibitor of Wnt signalling and thus regulates bone formation and homeostasis. In metabolic bone disorders such as diabetes mellitus, chronic kidney disease and obesity‐related osteoporosis, dysregulated sclerostin expression emerges as a key driver of skeletal fragility despite often normal or elevated bone mineral density. Elevated glucose levels and advanced glycation end-products accumulate in bone matrix, augment sclerostin production and impair osteoblast activity, leading to reduced bone quality. Conversely, therapeutic modulation of sclerostin has demonstrated potential to restore bone mass and improve strength. Recent work highlights both systemic endocrine actions of sclerostin—linking bone to energy metabolism—and local effects within the lacunar-canalicular network, where sclerostin accumulation may promote matrix degradation. Understanding the balance between circulating and locally retained sclerostin is essential for the development of targeted interventions that address the global burden of metabolic bone disease and its impact on fracture risk.

Research from Nature Portfolio

Elevated glucose levels have been shown to act directly on osteocytes in vitro, driving a marked increase in sclerostin gene and protein expression. In diabetic animal models, hyperglycaemia induces persistent osteocytic sclerostin upregulation, which correlates with impaired bone formation markers and reduced bone quality. These foundational findings reveal a direct mechanistic link between glucose dysregulation and sclerostin-mediated inhibition of bone anabolism, suggesting that glucose control may be critical to preserving skeletal integrity in diabetes.

Sclerostin Dynamics in Metabolic Bone Disorders publication trend

The graph below shows the total number of articles in sclerostin dynamics in metabolic bone disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Sclerostin: A glycoprotein produced by osteocytes that inhibits Wnt signalling, thereby limiting bone formation.

Osteocyte: A terminally differentiated bone cell embedded within the mineralised matrix that orchestrates bone remodelling.

Wnt signalling: A molecular pathway essential for osteoblast differentiation and bone formation, blocked by sclerostin’s interaction with LRP co-receptors.

Advanced glycation end-products (AGEs): Non-enzymatic glycation products that accumulate in the bone matrix, compromise material properties and promote sclerostin expression.

Lacunar-canalicular system (LCS): A network of interconnected spaces housing osteocytes and facilitating nutrient and signal exchange within bone tissue.

References

1. Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength. eLife (2024).
2. Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes. Scientific Reports (2019).
3. Evaluating the correlation of sclerostin levels with obesity and type 2 diabetes in a multiethnic population living in Kuwait. Frontiers in Endocrinology (2024).
4. Localized sclerostin accumulation in osteocyte lacunar-canalicular system is associated with cortical bone microstructural alterations and bone fragility in db/db male mice. Frontiers in Cell and Developmental Biology (2025).